Medpace Holdings(MX:MEDP)
MX$7,022.030.00 (0.00%)
MX:MEDP
Medpace Holdings stock drug pipeline
MX$7,022.03
At close:0.00 (0.00%)
Medpace Holdings (MEDP) Drug Pipeline
1 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Medpace Holdings Inc (MX:MEDP) have in its pipeline
Medpace Holdings MX:MEDP is currently developing the following drugs: [68Ga]Bed003, Sham Procedure, Rugonersen, [18F]Fpyqcp, 177Lu-Betabart, 177Lu-Tlx250, Lerodalcibep 300 Mg Monthly Sc, Rad101, Lutetium Rhpsma 10.1 And Pluvicto, Sevasemten, Azeliragon, Tnx-103, Chs-006, Toripalimab, Sevasemten 10 Mg, Sevasemten 5 Mg, Sevasemten 12.5 Mg, Meropenem, Cefepime-Zidebactam, Avm0703, Avacopan, Investigator's Choice, Pritelivir, Men1703. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

